XML 59 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue Recognition - Additional Information (Detail)
¥ in Billions
 1 Months Ended 3 Months Ended 9 Months Ended
May 17, 2018
USD ($)
item
Apr. 30, 2013
USD ($)
item
Apr. 30, 2012
USD ($)
Sep. 30, 2020
USD ($)
Milestone
Sep. 30, 2019
USD ($)
Milestone
Sep. 30, 2020
USD ($)
item
Sep. 30, 2019
USD ($)
Milestone
Dec. 31, 2019
USD ($)
Apr. 30, 2013
JPY (¥)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Deferred revenue, current       $ 511,000   $ 511,000   $ 22,262,000  
Total revenue       $ 9,266,000 $ 5,785,000 22,993,000 $ 15,375,000    
Number of milestone event probable of occurrence or achieved | Milestone       0 0   0    
License and Milestone Fees                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Total revenue       $ 9,257,000 $ 5,785,000 22,377,000 $ 15,235,000    
Royalty [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue from contract with customer           0      
VFMCRP Agreement [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Deferred revenue, current       511,000   511,000   22,262,000  
Deferred revenue, non current       0   0   0  
Receivables       0   0   0  
Other assets       0   0   0  
Deferred revenue $ 55,444,000                
Number of combined performance obligations for revenue recognized | item 1                
Number of performance obligations for revenue recognized | item 2                
upfront payment $ 50,000,000                
Premium from sale of stock $ 5,444,000                
Remaining performance obligations       $ 511,000   $ 511,000      
Remaining performance obligation, expected timing of satisfaction, year       2020   2020      
VFMCRP Agreement [Member] | License and Milestone Fees                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Total revenue       $ 9,257,000   $ 21,751,000      
License and milestone fees recognized           54,933,000      
Maruishi and CKDP Agreements [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Deferred revenue, non current       0   0      
Receivables       0   0   0  
Other assets       $ 0   $ 0   0  
Deferred revenue               $ 0  
Number of remaining performance obligations | item           0      
Maruishi Agreement [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Number of performance obligations for revenue recognized | item   2              
Premium from sale of stock   $ 337,000              
Upfront non-refundable, non-creditable license fee and premium from sale of stock   15,337,000              
Maruishi Agreement [Member] | Clinical Development and Regulatory Milestones [Member] | Maximum [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Remaining potential consideration   10,500,000              
Maruishi Agreement [Member] | One-time Sales Milestone [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Remaining potential consideration | ¥                 ¥ 1
Maruishi Agreement [Member] | License [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Estimated selling price   10,200,000              
Upfront payments on obligations   9,637,000              
Maruishi Agreement [Member] | R&D Services [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Estimated selling price   6,200,000              
Upfront payments on obligations   $ 5,700,000              
CKDP Agreement [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Premium from sale of stock     $ 83,000            
CKDP Agreement [Member] | Clinical Development and Regulatory Milestones [Member] | Maximum [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Remaining potential consideration     3,750,000            
CKDP Agreement [Member] | License and Milestone Fees                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Total revenue           $ 626,000      
CKDP Agreement [Member] | License [Member]                  
Research and Development Arrangement, Contract to Perform for Others [Line Items]                  
Revenue from contract with customer     $ 646,000